Clinical trials: PostPartum Depression
PostPartum Depression
Curio Digital Therapy for the Treatment of Post-partum Depression
Primary Objective: Evaluate the clinical effectiveness of the MamaLift Plus app compared to control (digital sham plus treatment as usual) for the management of PPD in the observed population for a period of 9 calendar weeks.
- Trial name
- SuMMER (NCT05958095)
- Testing
- MamaLift Plus
- Where
- United States
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Healthcare Innovation Technology Lab
Depression, Postpartum, Postpartum Depression
A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression
The purpose of this research study is to test the study drug, NORA520, as a possible treatment for severe postpartum depression (PPD).
- Conditions
- Depression, Postpartum, Postpartum Depression, Post-partum Depression, Postnatal Depression
- Trial name
- NuMom (NCT06285916)
- Testing
- NORA520 Dose 1, NORA520 Dose 2
- Where
- 18 sites in United States
- Volunteers
- 93 people
- Sponsor
- TWi Biotechnology, Inc.
Postpartum Depression, Postnatal Depression
Phase 2 Clinical Trial of GH001 in Postpartum Depression
This study is a multicenter, open-label, single-arm Phase 2 clinical trial. Approximately 15 female participants with clinically diagnosed postpartum depression (PPD) will be included in this study.
- Trial name
- NCT05804708
- Testing
- GH001
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 10 people
- Sponsor
- GH Research Ireland Limited
Postpartum Depression
Expanded Access Protocol of ZULRESSO™ (Brexanolone) Injection for Adult Patients With Postpartum Depression
This is an expanded access program intended to provide access to ZULRESSO™ (brexanolone) injection for the treatment of a limited number of eligible women with postpartum depression during the period prior to commercial…
- Trial name
- NCT03924492
- Testing
- ZULRESSO (brexanolone) injection
- Sponsor
- Supernus Pharmaceuticals, Inc.
Postpartum Depression
Evaluate SAGE-547 in Female Participants With Severe Postpartum Depression
This is an open-label proof-of-concept study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of SAGE-547 Injection in adult female participants diagnosed with severe postpartum depression (PPD).
- Trial name
- NCT02285504
- Testing
- SAGE-547
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Postpartum Depression
A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)
The purpose of this study was to determine if SAGE-547 Injection infused intravenously at up to 90 micrograms per kilogram per hour (μg/kg/h) for 60 hours reduces depressive symptoms in participants with severe postpartum…
- Trial name
- NCT02942004
- Testing
- SAGE-547 60 μg/kg/h, SAGE-547 90 μg/kg/h
- Where
- 32 sites in United States
- Volunteers
- 138 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Pregnancy Related, Mental Health Issue
MamaConecta: Digital Tool for Maternal Mental Health
The goal of this randomized controlled trial is to validate a digital health tool, Dana app, that enhances well-being and supports mental health monitoring for women during the perinatal period.
- Conditions
- Pregnancy Related, Mental Health Issue, Postpartum Depression, Postpartum Anxiety
- Trial name
- DDT (NCT06442774)
- Testing
- Mobile application, Monitoring via wearable
- Where
- 3 sites in Spain
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- A Thousand Colibris, S.L
Postpartum Depression (PPD)
SAINT in Postpartum Depression (PPD)
This study is a large, multi-site clinical trial testing whether Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), a fast-acting form of repetitive transcranial magnetic stimulation (rTMS), can more effectively…
- Trial name
- NCT07210255
- Testing
- SAINT Neuromodulation System
- Where
- 4 sites in United States
- Volunteers
- 192 people
- Sponsor
- Magnus Medical
COVID-19, Pregnancy Complications
Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic
The purpose of this study is to assess the health and wellbeing of pregnant and recently pregnant women during the COVID-19 pandemic using an online survey.
- Conditions
- COVID-19, Pregnancy Complications, Mental Health Wellness 1, Anxiety
- Trial name
- NCT04385238
- Testing
- This is an online survey with no intervention.
- Where
- United States
- Volunteers
- 6,894 people
- Sponsor
- Pregistry
Postpartum Depressive Disorder
Quetiapine in Postpartum Depression
The purpose of the study is to evaluate the efficacy and tolerability of quetiapine in female patients with postpartum depressive disorder with psychotic symptoms
- Trial name
- NCT00681668
- Testing
- Quetiapine
- Where
- Germany
- Volunteers
- 5 people
- Sponsor
- AstraZeneca
Depression, Postpartum, Postpartum Depression (PPD)
Brexanolone Lifting Outcomes Of Moms
The purpose of this research study is to test the study drug, LPCN 1154A, as a possible treatment for postpartum depression (PPD).
- Conditions
- Depression, Postpartum, Postpartum Depression (PPD), Post-partum Depression, Postnatal Depression
- Trial name
- BLOOM (NCT07822321)
- Testing
- LPCN 1154A
- Where
- 16 sites in United States
- Volunteers
- 120 people
- Sponsor
- Lipocine Inc.
Depression, Postpartum
A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)
The purpose of this study is to determine if treatment with SAGE-217 reduces depressive symptoms in females with severe postpartum depression (PPD) as compared to placebo.
- Trial name
- NCT04442503
- Testing
- SAGE-217
- Where
- 82 sites in United States, Spain and 1 more
- Volunteers
- 200 people
- Sponsor
- Biogen
Depressive Symptoms, Urinary Incontinence
BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Urinary Incontinence in Postpartum and Early Post-Childbirth Women
The goal of this clinical trial is to evaluate if the combined treatment with EXOMIND (BTL-699-2) and EMSELLA (HPM-6000UF) devices is able to improve depressive symptoms and urinary incontinence in women who delivered a healthy…
- Trial name
- NCT07413692
- Testing
- EXOMIND (BTL-699-2) ActiveTreatment, EMSELLA (HPM-6000UF) ActiveTreatment
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- BTL Industries Ltd.
Severe Postpartum Depression
A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression
This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the efficacy, safety, and pharmacokinetics of SAGE-547 Injection in adult female participants diagnosed with severe postpartum…
- Trial name
- NCT02614547
- Testing
- SAGE-547
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Pregnancy, Migraine
External Trigeminal Nerve Stimulation for Migraine Treatment in Pregnancy
This online registry aims to understand the potential benefits and safety of external trigeminal nerve stimulation for the treatment of migraine in pregnant women.
- Conditions
- Pregnancy, Migraine, Headache, Postpartum
- Trial name
- NCT06788977
- Testing
- external Trigeminal Nerve Stimulation
- Where
- United States
- Volunteers
- 550 people
- Sponsor
- Cefaly Technology
Postpartum Depression
[Study Evaluating the Efficacy and Safety of a Digital Therapeutic as an Adjunct to TAU in Postpartum Depression]
This study evaluates the efficacy of two digital therapeutics, WB001 and ED001, on depressive symptoms among women diagnosed with postpartum depression.
- Trial name
- NCT05551195
- Testing
- WB001, ED001
- Where
- 8 sites in United States
- Volunteers
- 7 people
- Sponsor
- Woebot Health
Postpartum Depression
A Study to Evaluate Multimodal Neuroimaging Parameters in Women With Postpartum Depression Who Are Receiving ZULRESSO™ (Brexanolone)
In this Phase 4 study, women who have been prescribed commercial ZULRESSO™ (brexanolone) by a physician as standard of care for postpartum depression (PPD) and who are planning to receive the infusion per United States…
- Trial name
- NCT04273191
- Testing
- Brexanolone
- Sponsor
- Sage Therapeutics
Depression, Postpartum
A Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants Who Took it Within 1 Year After The End of Their Pregnancy
In this study, researchers will learn more about how zuranolone affects the symptoms of postpartum depression, also known as PPD. Zuranolone is a drug that healthcare professionals can prescribe for adults with PPD.
- Trial name
- NCT07047820
- Testing
- Zuranolone
- Where
- United States
- Volunteers
- 305 people
- Sponsor
- Biogen
Postpartum Depression
A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms in People Starting Zuranolone
In this study, researchers will learn how postpartum depression symptoms may change after people first start taking zuranolone. This is a drug available for doctors to prescribe for people with postpartum depression, also known…
- Trial name
- NCT07398469
- Testing
- Zuranolone
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Biogen
Infantile Colic, Infant Sleeping Habits
Role of ProTectis on Infant Colic and Its Effect on Infant Crying Time and Maternal Mental Health
This study will work on hypothetical assumption that compared to the arm supplemented with placebo (control) group; the L reuteri (intervention) group will lower daily crying/fussing time per 24 hours at one month post…
- Conditions
- Infantile Colic, Infant Sleeping Habits, Maternal Mental Health.
- Trial name
- PRIC-SMM (NCT02094092)
- Testing
- ProTectis drops (five drops per day) for 21 days
- Where
- Pakistan
- Volunteers
- 60 people
- Sponsor
- Ferozsons Laboratories Ltd.